Ami FadiaManaging Director, Biopharma and Generics, Senior Analyst at SVB Leerink
Ami Fadia is a senior analyst at SVB Leerink covering companies in Biopharma focused on Infectious Disease, Pain, Women’s Health and Generics. Ms. Fadia has spent over six years as a healthcare equity research analyst and also has significant experience as an adviser and executive in the pharmaceutical industry. Over the course of her career, Ms. Fadia served as Director of Specialty Pharmaceuticals and Generics Equity Research at UBS, where she built out lead coverage on small and mid-cap specialty pharmaceutical stocks and supported the existing large cap coverage effort. Prior to UBS, Ms. Fadia worked in the Sandoz Biosimilar business unit at Novartis, and earlier in her career Ms. Fadia was a consultant and engagement manager at KPMG and McKinsey & Co. Ms. Fadia received her M.B.A from the Kellogg School of Management at Northwestern University, and earned an undergraduate degree in Accounting, Finance and Taxation from Shri Ram College of Commerce in New Delhi, India. She also received her accreditation of Associate Chartered Accountant from the Institute of Chartered Accountants of India.